线粒体补充剂改善了自闭症患者的功能和线粒体活动:双盲安慰剂控制的交叉试验
Zoë Hill1, Patrick J McCarty2, Richard G Boles3,4
1Autism Discovery and Treatment Foundation, Phoenix, AZ 85050, USA.
International journal of molecular sciences
|March 27, 2025
概括
一种线粒体食补充剂改善了儿童的线粒体功能和自闭症谱系障碍 (ASD) 症状. 这种治疗为ASD管理提供了一个有希望的,耐受性良好的选择,解决了对有效干预的关键需求.
科学领域:
- 生物化学 生物化学
- 神经科学是一个神经科学.
- 儿科 儿科 儿科
背景情况:
- 自闭症谱系障碍 (ASD) 经常与线粒体功能障碍有关.
- 针对针对ASD线粒体问题的有效治疗方法存在有限的研究.
研究的目的:
- 评估一种针对线粒体的食补充剂,以改善儿童的线粒体功能和ASD症状.
- 评估补充剂在双盲,安慰剂控制,交叉设计中的有效性.
主要方法:
- 十六名患有自闭症和线粒体异常的儿童分别接受了向补充剂或安慰剂12周.
- 使用MitoSwab和海马XFe96试验评估了线粒体功能.
- 家长评级的尺度测量了神经发育,社会退缩和多动性的变化.
主要成果:
- 补充剂使特定的线粒体酶活动正常化 (酸盐合成酶,复合物IV).
- 周围血液单核细胞呼吸显示出治疗后对氧化应激的抵抗力增加.
- 在父母评估的神经发育,社会退缩和过度活跃性 (科恩d = 0.77-1.25) 中观察到显著的改善.
结论:
- 一种简单,耐受良好的线粒体补充剂可以增强线粒体生理学和减少ASD症状.
- 这种干预显示出作为ASD和线粒体异常的儿童有效治疗的潜力.
- 需要进行更大规模的研究来证实这些对ASD管理的有希望的发现.
相关概念视频
Blind Procedures
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which child was...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...


